Suppr超能文献

分子对接、动力学以及[具体对象]多靶点抑制剂的分析

Molecular docking, dynamics and analysis of multi-target inhibitors for .

作者信息

Golchha Nikita Chordia, Abdulhameed Odhar Hasanain, Nighojkar Anand, Nighojkar Sadhana

机构信息

School of Biotechnology, Devi Ahilya University, Takshashila Campus, Khandwa Road, INDORE-452001, India.

Department of Pharmacy, Al-Zahrawi University College, Karbala, Iraq.

出版信息

Bioinformation. 2024 Jan 31;20(1):39-48. doi: 10.6026/973206300200039. eCollection 2024.

Abstract

The opportunistic pathogen, owes its extreme pathogenicity for its ability to develop antibiotic resistance and recurrent infections. The current antibiotics used for the treatment are showing declining sensitivity and rising antibiotic resistance. Therefore, it is of interest to develop the anti-clostridial drugs to overcome these issues. Hence, we have explored ZINC library to find the suitable lead compounds against five target proteins of . Multistep virtual screening is performed to find the suitable compounds that are checked for their stability using molecular dynamics and are validated against . In our study, five compounds viz., ZINC64969876, ZINC13641164, ZINC13691348, ZINC5554596 and ZINC3894278 that inhibit HisC, Spo0A, PdcA, DAHP synthase and cyclic-di GMP proteins, respectively have been identified. Further, these compounds were tested against four different isolates of and all of them were found to inhibit the pathogen. However, to use these compounds as anti-clostridial drugs, further testing needs to be done. The selected compounds from our study are reported for the first time as antimicrobial agents against .

摘要

这种机会致病菌因其产生抗生素耐药性和反复感染的能力而具有极强的致病性。目前用于治疗的抗生素敏感性在下降,抗生素耐药性在上升。因此,开发抗梭菌药物以解决这些问题具有重要意义。为此,我们探索了ZINC文库,以寻找针对[具体细菌名称]五种靶蛋白的合适先导化合物。进行了多步虚拟筛选,以找到合适的化合物,使用分子动力学检查其稳定性,并针对[具体参照标准]进行验证。在我们的研究中,已鉴定出五种分别抑制HisC、Spo0A、PdcA、DAHP合酶和环二鸟苷酸蛋白的化合物,即ZINC64969876、ZINC13641164、ZINC13691348、ZINC5554596和ZINC3894278。此外,这些化合物针对[具体细菌名称]的四种不同分离株进行了测试,发现它们均能抑制该病原体。然而,要将这些化合物用作抗梭菌药物,还需要进一步测试。我们研究中所选的化合物作为针对[具体细菌名称]的抗菌剂首次被报道。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ca1/10859948/ca5fd1a3df4e/973206300200039F1.jpg

相似文献

1
Molecular docking, dynamics and analysis of multi-target inhibitors for .
Bioinformation. 2024 Jan 31;20(1):39-48. doi: 10.6026/973206300200039. eCollection 2024.
4
Recent development of small-molecular inhibitors against Clostridioides difficile infection.
Bioorg Chem. 2022 Aug;125:105843. doi: 10.1016/j.bioorg.2022.105843. Epub 2022 Apr 30.
5
Discovery of potential phytochemicals as inhibitors of TcdB, a major virulence factors of .
J Biomol Struct Dyn. 2023;41(22):12768-12776. doi: 10.1080/07391102.2023.2167120. Epub 2023 Jan 16.
6
Antibiotic Resistances of Clostridioides difficile.
Adv Exp Med Biol. 2024;1435:169-198. doi: 10.1007/978-3-031-42108-2_9.
7
Antibiotic resistance and genomic features of in southwest China.
PeerJ. 2022 Sep 5;10:e14016. doi: 10.7717/peerj.14016. eCollection 2022.
8
Diversity, Dynamics and Therapeutic Application of Bacteriophages.
Viruses. 2022 Dec 12;14(12):2772. doi: 10.3390/v14122772.
9
Antimicrobial Activity of Tannic Acid and Its Protective Effect on Mice against Clostridioides difficile.
Microbiol Spectr. 2023 Feb 14;11(1):e0261822. doi: 10.1128/spectrum.02618-22. Epub 2022 Dec 20.

本文引用的文献

1
Checkpoint Inhibitor Colitis With Superimposed Clostridioides difficile Infection.
Cureus. 2023 Apr 1;15(4):e37006. doi: 10.7759/cureus.37006. eCollection 2023 Apr.
2
Corrigendum: Structure-guided design of a potent toxin A inhibitor.
Front Microbiol. 2023 Mar 30;14:1167817. doi: 10.3389/fmicb.2023.1167817. eCollection 2023.
3
Clinical Impact of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Associated Infection Among Patients with Lung Cancer.
Onco Targets Ther. 2022 Dec 28;15:1563-1571. doi: 10.2147/OTT.S386807. eCollection 2022.
4
Redefining genomic view of through pangenome analysis and identification of drug targets from its core genome.
Drug Target Insights. 2022 Nov 11;16:17-24. doi: 10.33393/dti.2022.2469. eCollection 2022 Jan-Dec.
5
A case of refractory immune checkpoint inhibitor-induced colitis with infection.
DEN Open. 2022 Oct 17;3(1):e176. doi: 10.1002/deo2.176. eCollection 2023 Apr.
6
Discovery of a novel natural product inhibitor of Clostridioides difficile with potent activity in vitro and in vivo.
PLoS One. 2022 Aug 8;17(8):e0267859. doi: 10.1371/journal.pone.0267859. eCollection 2022.
7
Proton Pump Inhibitor-Induced Gut Dysbiosis Increases Mortality Rates for Patients with Clostridioides difficile Infection.
Microbiol Spectr. 2022 Aug 31;10(4):e0048622. doi: 10.1128/spectrum.00486-22. Epub 2022 Jul 6.
8
Clostridioides difficile infection (CDI) during the COVID-19 pandemic.
Anaerobe. 2022 Apr;74:102518. doi: 10.1016/j.anaerobe.2022.102518. Epub 2022 Jan 19.
9
Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis.
Antimicrob Resist Infect Control. 2020 Sep 25;9(1):158. doi: 10.1186/s13756-020-00815-5.
10
Ultrapotent Inhibitor of Growth, Which Suppresses Recurrence .
J Med Chem. 2020 Oct 22;63(20):11934-11944. doi: 10.1021/acs.jmedchem.0c01198. Epub 2020 Oct 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验